DBV Technologies (NASDAQ:DBVT) Stock Price Up 6.2% – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT) was up 6.2% during mid-day trading on Monday . The stock traded as high as $14.77 and last traded at $14.8850. 45,287 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 304,978 shares. The stock had previously closed at $14.02.

Analyst Upgrades and Downgrades

DBVT has been the subject of a number of research reports. Weiss Ratings cut DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Citizens Jmp increased their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Guggenheim restated a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research note on Monday, May 4th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. Finally, Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, DBV Technologies currently has an average rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Trading Down 1.4%

The company has a 50-day simple moving average of $15.15 and a 200 day simple moving average of $18.57. The firm has a market cap of $909.87 million, a PE ratio of -4.12 and a beta of -0.93.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The business had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.90 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. On average, equities analysts expect that DBV Technologies S.A. will post -2.05 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

Hedge funds have recently modified their holdings of the business. Artisan Partners Limited Partnership raised its stake in DBV Technologies by 6,273.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after purchasing an additional 3,257,135 shares during the period. Vivo Capital LLC grew its stake in shares of DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after buying an additional 205,943 shares during the period. Siren L.L.C. purchased a new stake in shares of DBV Technologies in the 4th quarter valued at approximately $35,606,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $9,659,000. Finally, MPM Bioimpact LLC acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $9,649,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.